symptoms of disturbed sleep has been linked with more severe forms of depression [2] [3] [4] and poorer depression treatment response [5] . The underlying neurobiological links between disturbed sleep and mood remain, however, obscure.
Adolescence is marked by an increased incidence of depression and insomnia and dramatic changes in sleep patterns [6] . The trajectory of the maturational changes in sleep structure during adolescence matches, temporally and topographically, adolescent brain cortical maturation. Both the decrease in deep slow-wave sleep and cortical grey matter reduction start from the occipital posterior regions and occur latest in the higher-order association areas of the frontal cortex [7] [8] [9] . Frontal cortex developmental processes continue until adulthood [10] , making the frontal cortex still vulnerable to aberrations in development during late adolescence [11] .
The prefrontal cortex (PFC), which is importantly involved in self-referential processing and the regulation of mood states via its interactions with striatal and limbic structures, has been repeatedly implicated as a key brain region involved in the pathophysiology of depression across diverse age groups [12, 13] . In depressed adolescents, both structural and functional changes in the PFC have been reported, i.e., a trend towards decreased regional volumes, abnormal cortical thinning, and reduced activation in cognitive control and decision-making tasks [13] . The structure and function of the PFC have likewise been observed to correlate with sleep habits [14] [15] [16] , sleep loss [17, 18] , and sleep pathologies [19] [20] [21] .
Proton magnetic resonance spectroscopy ( 1 H MRS) affords the detection and measurement in vivo of several neurometabolites, which enable the examination of the distinct neurochemical processes involved in the pathophysiology of depression. In depressed adolescents, 1 H MRS has revealed numerous but inconsistent findings in the frontal cortex. Both higher and lower levels of choline-containing compounds (Cho) have been reported in the medial frontal cortex and the left dorso-lateral PFC (DLPFC) [22] [23] [24] , higher myo-inositol (mI) levels have been observed in the DLPFC [24] , and lower glutamate plus glutamine (Glx) and N-acetyl-aspartate (NAA) concentrations in the anterior cingulate cortex (ACC) have been found [13, 25, 26] . The first and, so far, only attempt to study the link between sleep, mood, and frontal 1 H MRS neurochemistry in young people with affective disorders found that a later sleep midpoint is associated with altered glutamatergic processes in the ACC, independent of depression severity [27] . In that study, diurnal rhythm and motor activity were measured by actigraphy from a rather heterogeneous group of adolescents and young adults (age range: 15-33 years) with an emerging unipolar or bipolar disorder [27] .
MRS findings suggest that cellular health and neurotransmission might be impaired in the frontal cortical areas in adolescents with depression. It seems possible that sleep would also affect the same neurometabolic processes. However, the findings still remain inconsistent for several reasons. Most notably, the number of subjects studied is typically small in 1 H MRS studies, and the samples have been heterogeneous in terms of age, pubertal status, gender, psychotropic medication use, and the presence of other psychiatric comorbidities. Furthermore, the methodological approaches and brain areas studied have been variable.
We hypothesized that frontal cortex 1 H MRS neurochemistry would be altered in depressed adolescents versus healthy controls. Further, we hypothesized that sleep symptoms would be associated with metabolite levels in a similar way to depressive symptoms. We studied this in a carefully evaluated and selected homogeneous sample of non-medicated adolescent boys, and performed 1 H MRS in 2 frontal cortical regions (the ACC and DLPFC), and also in frontal white matter (FWM; a control region with no hypothesis of altered metabolism) with a 3-T MR imager.
Materials and Methods

Participants
A total of 20 non-medicated adolescent boys participated in the study. Ten of them were patients suffering from depressive and/or sleep symptoms recruited from the Helsinki University Central Hospital Department of Adolescent Psychiatry outpatient units, and 10 were healthy controls recruited via advertisements for the hospital staff. Imaging data was not available for 1 adolescent in the patient group due to drop-out, leaving a total of 19 participants in the analyses presented. Written informed consent for study participation was received both from the participants and their parents or legal guardians, and the study protocol was approved by the hospital ethics committee.
Exclusion criteria for all participants included mental retardation, insufficient knowledge of the Finnish language, current use of medication, age >17.5 or <14.5 years, chronic somatic illness, substance abuse/dependence, a principal DSM-IV diagnosis other than depressive/sleep disorder, and any contraindications for brain MRI. All adolescents were free of psychotropic and other medication during the whole study period. No structural pathologies were found in their brain anatomy according to brain MRI evaluated by a neuroradiologist (N.L.), and the presence of somatic conditions was ruled out based on blood samples. All subjects consumed <3 cups of coffee daily or the equivalent amount of other caffeinated products. Detailed subject characteristics are described in Table 1 .
Psychiatric Evaluation
The present and lifetime episodes of DSM-IV Axis I disorders were assessed with the Schedule for Affective Disorders and Schizophrenia for School-Age Children -Present and Lifetime version (K-SADS-PL), a semi-structured diagnostic interview [28] . All interviews were performed by the same clinician (A.S.U.) and confirmed in a diagnostic meeting with a senior clinician (M.M.). As part of the DSM-IV axial diagnostic procedure, the Global Assessment of Functioning (GAF) scale (numeric range: 0-100) was used according to DSM-IV guidelines to assess overall psychosocial functioning [1] . The GAF scale has been used previously in studies on adolescents [29, 30] .
Depression symptom severity was assessed with 2 different scales: the 21-item Beck Depression Inventory (BDI-21), and the Hamilton Depression Rating Scale (HDRS). The BDI-21 is a standardized, self-rating questionnaire [31] , well-used, also for studying adolescents [32, 33] . The subjects were asked to rate each of the symptoms on a 4-point scale ranging from 0 (not at all) to 3 (severely) according to the severity of the symptom (sum score range: 0-63). The HDRS is a widely used and standardized 17-item depression severity scale; each depressive symptoms is rated by the clinician on a scale of 0-2 or 0-4 points (total sum score range: 0-52) [34] . The HDRS was originally developed for adults but has also been successfully applied to study adolescents [4, [35] [36] [37] .
To complement the psychiatric evaluation, the subjects also filled in the Alcohol Use Disorder Identification Test (AUDIT) [38] , and the Beck Anxiety Inventory (BAI) [39] .
Assessment of Sleep
Insomnia symptoms were assessed with the Athens Insomnia Scale (AIS), a validated, self-report questionnaire designed for quantifying sleep difficulties during the past month based on the ICD-10 criteria [40] . It consists of 8 items, rated on a scale of 0-3 (total sum score range: 0-24), on sleep induction, awakenings during the night, final awakening, total sleep duration, sleep quality, daytime well-being, daytime functioning capacity, and sleepiness during the day.
Daytime sleepiness symptoms were measured with the Pediatric Daytime Sleepiness Scale (PDSS) [41] , a self-rated sleepiness scale specially designed for use among school-aged adolescents. The PDSS consists of 8 items, rated on a scale of 0-4 (total sum score range: 0-32), related to the frequency of falling asleep/drowsiness in class and while doing homework, daytime alertness, daytime tiredness/grumpiness, trouble waking up, falling back to sleep after being awakened, the need for outside help to wake up, and thoughts of needing more sleep.
Sleep length and sleep efficiency referred to sleep period were assessed with ambulatory polysomnography performed in the home environment for 2 consecutive nights. The recordings included electroencephalogram (EEG), electro-oculogram (EOG), and chin electro-myogram (EMG) recordings, performed using standard guidelines (Embla, Flaga Hf. Medical devices; EEG positions according to the international 10-20 system; derivations F4-M1, C4-M1, O2-M1 and back-up derivations F3-M2, C3-M2, and O1-M2; sampling rate 200 Hz). The recordings were scored manually in 30-s epochs by a certified sleep technologist blinded to the subgroup status of the subjects and using standard criteria [42] . Total sleep time and sleep efficiency (time asleep relative to sleep period) were calculated from the scorings. The average values of the 2 nights were used in the analyses. Table 1 . Sample characteristics presented separately for the total sample (n = 19), and the cases (n = 9) and controls (n = 10) BMI, body mass index; S-testo, serum testosterone level; BDI-21, 21-item Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale; BAI, Beck Anxiety Inventory; GAF, Global Assessment of Functioning Scale; AIS, Athens Insomnia Scale; PDSS, Pediatric Daytime Sleepiness Scale; TST, total sleep time. * p < 0.05, statistically significant differences between cases and controls; ** p < 0.001, statistically significant differences (one-way ANO-VA). Marttunen/Lundbom //s-provencher.com/pages/lcmodel.shtml) was used to assess the concentrations of NAA, total creatine (tCr), Cho, Glx, and mI. Signal-to-noise ratio (SNR) and full width at half maximum (FWHM) were determined. The typical location of the 1 H MRS voxels and representative 1 H MR spectra are shown in Figure 1 .
Magnetic Resonance Spectroscopy
Statistical Analyses
Statistical analyses were performed with the IBM SPSS v22 software. Normality of the data was assessed with the KolmogorovSmirnov test of normality. Comparisons between subgroups were performed with one-way analysis of variance (ANOVA), or the nonparametric independent-samples Kruskal-Wallis test in the case of non-normal distribution of the data. To assess correlations between mI concentrations and clinical measures (total sleep time [TST], sleep efficiency, BDI-21 total score, and HDRS, BAI, AIS, PDSS, and GAF scores), correlation analyses using the Pearson correlation analysis or the Spearman non-parametric correlation analysis (in the case of non-normal distribution of the data) were performed. Findings were considered statistically significant at p < 0.05.
Results
Participant Characteristics
Participants were on average 16.0 ± 0.8 (mean ± SD) years old. The subgroups of cases and controls did not differ in terms of their age, body mass index, serum testosterone levels, alcohol use, or anxiety symptoms (oneway ANOVA; ns; Table 1 ) .
No Axis I diagnoses were found among the controls, and the cases were confirmed to suffer from depressive disorder (a lifetime first depressive episode for 6 and a second episode for 2 subjects; mean length of current depressive episode 52 ± 52 weeks), except for 1 patient who was suffering from only a circadian rhythm sleep disorder with minor mood symptoms. This non-depressed subject was discarded from the group comparisons, but his data was used in the correlational analyses of the total sample. None of the subjects suffered from bipolar disorder or manifested psychotic features of depression. Comorbid anxiety disorder was present in 1 subject and comorbid disruptive behaviour disorder in 1 subject, and the others did not have comorbid Axis I disorders.
Quality of the 1 H MRS Spectra
Mean SNRs for ACC, DLPFC, and FWM spectra were 46 ± 7.38 ± 6, and 21 ± 5, respectively. FWHMs for ACC, DLPFC, and FWM spectra were 4.5 ± 1.2 Hz, 5.7 ± 1.7 Hz, and 6.3 ± 2.3 Hz, respectively. There were no differences in ACC, DLPFC, and FWM spectral quality between the control and patient groups measured by SNR or FWHM. Cramer-Rao lower bound values for mI quantification , and FWM ( c ), and the corresponding spectra from the ACC ( d ), DLPFC ( e ), and FWM ( f ). ACC, anterior cingulate cortex; DLPFC, left dorsolateral prefrontal cortex; FWM, frontal white matter; tCr, total creatine; mI, myo-inositol; Cho, cholinecontaining compounds; Gln, glutamine; Glu, glutamate; NAA, Nacetyl aspartate.
were ≤ 7% in all spectra. Due to technical failure or the movement of a patient, MRS spectra could not be obtained in 2 cases in the DLPFC area (limiting the total sample size to 17) and in 1 case in the FWM (limiting the total sample size to 16).
Subgroup Comparisons of Metabolite Concentrations
The concentration of mI was lower in the cases than in the controls in both frontal cortical areas (ACC: F 1, 16 = 10.026; p = 0.006; DLPFC: F 1, 14 = 5.381; p = 0.036; one-way ANOVA; Fig. 2 ). No significant differences were observed in the concentrations of the other metabolites in either of these cortical brain areas or in any of the metabolite concentrations in the FWM (one-way ANOVA or independent-samples Kruskal-Wallis test; ns; Fig. 2 ).
Metabolites and Clinical Measures
In the total sample, mI levels in the ACC correlated negatively with depression severity (HDRS and BDI-21), level of anxiety (BAI), insomnia symptoms (AIS), daytime sleepiness symptoms (PDSS), and correlated positively with TST ( Fig. 3 ) and overall psychosocial functioning (GAF). The mI level in the DLPFC correlated negatively with depression severity (HDRS) and positively with TST. Other correlations of mI with clinical measures remained statistically non-significant. The results are presented in detail in Table 2 .
In order to examine whether the significant associations between mI and sleep measures are confounded by depressive symptoms, we performed additional partial correlation analyses, in which depression severity was controlled for (partial correlation analyses; BDI-21 total 
Discussion
The main finding of this study was that frontal cortex mI was lower in depressed adolescent boys than in healthy controls, and also correlated with sleep length and daytime sleepiness symptoms when controlling for severity of depression. This implies that poor sleep and depression may be linked to similar neurometabolic pathways in the frontal cortex. These metabolic alterations appear to be specific to the cortex since they were not observed in the FWM.
Myo-inositol is a naturally occurring glucose isomer which has a number of known roles in the brain. It was initially found in astrocytes, and was therefore proposed as a glia-specific marker [43] . It has, however, also been detected in neuronal cells [44] . It acts as an organic osmolyte involved in the maintenance of cell volume, is required for the synthesis of cell membrane phospholipids, and also acts as a precursor in the phosphatidylinositol (PI) second-messenger system [45, 46] . The PI cycle is activated following ligand binding to a number of cell surface receptors, including those for serotonin, glutamate, histamine, and dopamine. This leads to an increase in the second messengers inositol triphosphate (IP3) and diacylglycerol (DAG), which initiate different cascades of cellular events, including the mobilization of intracellular calcium and the activation of protein kinase C (PKC), which, in turn, have multiple downstream cellular effects [45, 46] . The source of neuronal mI is primarily the recycling of PI cycle constituents, but some of the total mI is synthesized in the brain from glucose and some is transported from the blood [47] . Our finding of lower mI in depressed adolescents with sleep symptoms may point towards an imbalance in the second-messenger signaling system.
Considering the extensive neurometabolic role that mI plays, it is not surprising that altered concentrations have been previously detected in a variety of neurological, psychiatric, and behavioural conditions, including head injuries, Alzheimer disease, attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder, and sleep and mood disorders in different age groups [48] [49] [50] [51] [52] [53] [54] [55] . It has been suggested that a reduced cerebral mI concentration is a neurochemical biomarker for depression; lower inositol has been reported in the cerebrospinal fluid of depressed patients [56] as well as in the frontal cortex of suicide victims (postmortem) and patients with bipolar disorder [57] . Some 1 H MRS studies have observed lower cerebral mI concentrations in depressed patients than in controls [48, [58] [59] [60] . On the contrary, bipo- lar disorder may be characterized by elevated frontal cortex mI concentrations, and the anti-manic effects of lithium may be associated with a reduction of mI [61] . Electro-convulsive treatment (ECT) may increase mI concentrations [60] . These results are not, however, unanimous, as some studies have reported increased or similar mI levels in depressed patients versus healthy controls [24, 62, 63] . Inositol is widely present in a range of foods (fruits, plants, meats, and whole-grain cereals) and also available as a dietary supplement. At present, there is no clear evidence that mI is of benefit in the treatment of depression [64] . The results of this study support earlier findings on decreased cortical mI levels in depression, particularly in the adolescent age group, and encourage further study of the role of mI in depression and associated sleep symptoms. Understanding these pathophysiological phenomena early in the course of depression could be crucial, not only in furthering our scientific understanding of the links between poor sleep and mood, but also in developing targeted, effective, and hopefully even preventive interventions [6] .
Less is known about the association of mI and sleep. In healthy older people, poorer sleep quality and less efficient sleep correlates with higher hippocampal mI/tCr ratios, hypothesized as being associated with hippocampal glial alterations [50] . The authors of that study point out, however, that their findings may actually reflect neurodegenerative/pathophysiological processes in this age group, similar to those seen in Alzheimer disease [50, 52, 65, 66] . The contrast between the findings of Cross et al. [49] (pointing towards a higher mI being linked to poor sleep in older people) and our findings (pointing towards a lower mI being linked to poor sleep in adolescents) may thus be at least partly explained by factors related to maturational or neurodegenerational processes. In addition, brain region-specific factors may also contribute to the differences, i.e., the mI concentration [46, 67] and neuronal activity during the sleep-wake cycle [68] differ between the hippocampal and frontal cortex areas. Cross et al. [49] concentrated on the hippocampus and did not obtain results for the frontal cortex and our study concentrated on frontal brain areas only. The frontal cortex (more specifically, the ACC) was the region of interest in the study by Naismith et al. [27] , who reported an association between sleep midpoint and altered glutamatergic processes among young people with affective disorders, but mI was not a neurometabolite of interest in their study.
To the best of our knowledge, our study is the first to demonstrate an association between subjective and objective sleep measures and frontal cortex mI concentrations in a sample of adolescent boys. We revealed that depressed adolescents showed lower cortical mI concentrations than healthy controls, but depression cannnot fully explain the association of mI with sleep length and daytime sleepiness. Both sleep length and depression may thus affect the same neurometabolic pathways in the maturing frontal cortex of adolescents in an additive manner.
In addition to the findings relating to mI, we found that tCr concentrations in the ACC correlated negatively with depression severity and insomnia symptoms. tCr has conventionally been used as a reference metabolite, and very few studies (with inconsistent findings) have assessed tCr concentrations in psychiatric disorders [69] . However, tCr is not a constant compound in the brain, but plays a pivotal role in cell energy homeostasis; thus, lower tCr levels related to insomnia and depressive symptoms may indicate impaired energy metabolism [46] . The fact that no significant findings were detected in other MRS metabolites may be attributed to the small sample size, which did not allow us to detect subtle differences.
Important strengths of this study include the homogeneous nature of the sample in terms of gender and age, the lack of psychotropic and other medication use among the subjects, the use of polysomnography (the gold standard of sleep research) to determine sleep length, the detailed psychiatric evaluation of the participants, and the inclusion of a control group. Furthermore, the patient and control groups were well-matched for their age and hormonal status. Since anti-depressive medication may at least region-specifically affect the brain MRS metabolic profile [70] , we found that the lack of psychotropic medication use was a particular strength of our study.
Limitations of the study include, most importantly, the small sample size, which allowed us to make only preliminary conclusions on the results. Further studies with larger samples are needed, especially to conduct more specific multi-variable analyses in subgroups. Our study was cross-sectional, so we cannot make definite inferences on causality, e.g., Are shorter sleep and depressive symptoms actually causing a change in mI metabolism? Or do the alterations in mI underlie the clinical phenotypes? This can only be answered by longitudinal study designs. Excluding female participants from the sample, on the one hand, limited the generalizability of the findings to adolescent girls, but, on the other, it also excluded the potential effects of the menstrual cycle on sleep and brain metabolism [71, 72] . Boys and girls also differ from each other in terms of brain maturational changes during adolescence [73] . Another limitation of this study was the lack of correction for partial volume effects. In theory, gray matter atrophy could lead to an increased cerebrospinal fluid fraction inside the volume-of-interest and thus decreased metabolite levels. Should this occur, a decrease in all metabolite levels and SNR would be expected, but we did not see any differences between groups with regard to other metabolites or SNR.
Conclusion
Lower frontal cortex mI may point towards a disturbed second-messenger system, and be linked to the pathophysiology of depression and concomitant sleep symptoms among maturing adolescents. Short sleep and daytime sleepiness may be associated with frontal cortex mI independently of depression. Further studies are needed to explore the role of mI in depression and associated sleep symptoms in more detail.
